319 related articles for article (PubMed ID: 23988185)
41. The hypermethylation of p16 gene exon 1 and exon 2: potential biomarkers for colorectal cancer and are associated with cancer pathological staging.
Ye X; Mo M; Xu S; Yang Q; Wu M; Zhang J; Chen B; Li J; Zhong Y; Huang Q; Cai C
BMC Cancer; 2018 Oct; 18(1):1023. PubMed ID: 30348132
[TBL] [Abstract][Full Text] [Related]
42. Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer.
Belshaw NJ; Elliott GO; Williams EA; Bradburn DM; Mills SJ; Mathers JC; Johnson IT
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1495-501. PubMed ID: 15342451
[TBL] [Abstract][Full Text] [Related]
43. Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer.
Gu S; Lin S; Ye D; Qian S; Jiang D; Zhang X; Li Q; Yang J; Ying X; Li Z; Tang M; Wang J; Jin M; Chen K
Clin Epigenetics; 2019 Mar; 11(1):41. PubMed ID: 30846004
[TBL] [Abstract][Full Text] [Related]
44. Methylation of FBN1, SPG20, ITF2, RUNX3, SNCA, MLH1, and SEPT9 genes in circulating cell-free DNA as biomarkers of colorectal cancer.
Alizadeh-Sedigh M; Fazeli MS; Mahmoodzadeh H; Sharif SB; Teimoori-Toolabi L
Cancer Biomark; 2022; 34(2):221-250. PubMed ID: 34957998
[TBL] [Abstract][Full Text] [Related]
45. The DNA hypermethylation phenotype of colorectal cancer liver metastases resembles that of the primary colorectal cancers.
Orjuela S; Menigatti M; Schraml P; Kambakamba P; Robinson MD; Marra G
BMC Cancer; 2020 Apr; 20(1):290. PubMed ID: 32252665
[TBL] [Abstract][Full Text] [Related]
46. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.
Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL;
BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170
[TBL] [Abstract][Full Text] [Related]
47. Septin 9 amplification and isoform-specific expression in peritumoral and tumor breast tissue.
Connolly D; Hoang HG; Adler E; Tazearslan C; Simmons N; Bernard VV; Castaldi M; Oktay MH; Montagna C
Biol Chem; 2014 Feb; 395(2):157-67. PubMed ID: 24127542
[TBL] [Abstract][Full Text] [Related]
48. Progress on the clinical application of the SEPT9 gene methylation assay in the past 5 years.
Song L; Li Y
Biomark Med; 2017 May; 11(6):415-418. PubMed ID: 28617104
[No Abstract] [Full Text] [Related]
49. Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening.
Zhao G; Li H; Yang Z; Wang Z; Xu M; Xiong S; Li S; Wu X; Liu X; Wang Z; Zhu Y; Ma Y; Fei S; Zheng M
Cancer Med; 2019 Sep; 8(12):5619-5628. PubMed ID: 31407497
[TBL] [Abstract][Full Text] [Related]
50. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients.
Yang X; Xu ZJ; Chen X; Zeng SS; Qian L; Wei J; Peng M; Wang X; Liu WL; Ma HY; Gong ZC; Yan YL
World J Gastroenterol; 2019 May; 25(17):2099-2109. PubMed ID: 31114136
[TBL] [Abstract][Full Text] [Related]
51. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report.
Powrózek T; Krawczyk P; Kucharczyk T; Milanowski J
Med Oncol; 2014 Apr; 31(4):917. PubMed ID: 24633736
[TBL] [Abstract][Full Text] [Related]
52. DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1, PTGDR and SFRP1 in colorectal adenoma and cancer.
Kalmár A; Péterfia B; Hollósi P; Galamb O; Spisák S; Wichmann B; Bodor A; Tóth K; Patai ÁV; Valcz G; Nagy ZB; Kubák V; Tulassay Z; Kovalszky I; Molnár B
BMC Cancer; 2015 Oct; 15():736. PubMed ID: 26482433
[TBL] [Abstract][Full Text] [Related]
53. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.
Tänzer M; Balluff B; Distler J; Hale K; Leodolter A; Röcken C; Molnar B; Schmid R; Lofton-Day C; Schuster T; Ebert MP
PLoS One; 2010 Feb; 5(2):e9061. PubMed ID: 20140221
[TBL] [Abstract][Full Text] [Related]
54. Identification of novel DNA methylation markers in colorectal cancer using MIRA-based microarrays.
Li H; Du Y; Zhang D; Wang LN; Yang C; Liu B; Wang WJ; Shi L; Hong WG; Zhang L; Yang YX
Oncol Rep; 2012 Jul; 28(1):99-104. PubMed ID: 22552777
[TBL] [Abstract][Full Text] [Related]
55. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G
BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473
[TBL] [Abstract][Full Text] [Related]
56. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma.
Potter NT; Hurban P; White MN; Whitlock KD; Lofton-Day CE; Tetzner R; Koenig T; Quigley NB; Weiss G
Clin Chem; 2014 Sep; 60(9):1183-91. PubMed ID: 24938752
[TBL] [Abstract][Full Text] [Related]
57. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
Ladabaum U; Allen J; Wandell M; Ramsey S
Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
[TBL] [Abstract][Full Text] [Related]
58. Performance of a Novel Blood-Based Early Colorectal Cancer Screening Assay in Remaining Serum after the Blood Biochemical Test.
Chen Y; Wang Z; Zhao G; Sun C; Ma Y; Zhang L; Zheng M; Li H
Dis Markers; 2019; 2019():5232780. PubMed ID: 31089394
[TBL] [Abstract][Full Text] [Related]
59. Plasma methylated septin 9: a colorectal cancer screening marker.
Molnár B; Tóth K; Barták BK; Tulassay Z
Expert Rev Mol Diagn; 2015 Feb; 15(2):171-84. PubMed ID: 25429690
[TBL] [Abstract][Full Text] [Related]
60. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay.
Grützmann R; Molnar B; Pilarsky C; Habermann JK; Schlag PM; Saeger HD; Miehlke S; Stolz T; Model F; Roblick UJ; Bruch HP; Koch R; Liebenberg V; Devos T; Song X; Day RH; Sledziewski AZ; Lofton-Day C
PLoS One; 2008; 3(11):e3759. PubMed ID: 19018278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
